Embark Healthcare
- Biotech or pharma, therapeutic R&D
We specialize in drug repurposing opportunities with strong IP and orphan protections. We have 3 assets available for acquisition/licensing: CIRARA (Remedy Pharma) for the treatment of large core ischemic stroke (Phase 3 ready) - inhibits the SUR1-TRPM4 channel to prevent edema formation, BRAVYL (Woolsey Pharma) for the treatment of Amyotrophic Lateral Sclerosis (Phase 2/3 ready) - a ROCK inhibitor that reduces Neurofilament Light (NfL) in ALS, and CIQUAAX (Martin Pharma) for the treatment of liver cirrhosis Ascites (Phase 2 ready) - an oral prodrug of dopamine.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}